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Background
Cardiac hypertrophy is an adaptive response of the heart
to many cardio-vascular disorders including hyperten-
sion, infarction and defects of the valves. Elevated levels
of cardiac cyclic guanosine-3’,5’-monophosphate (cGMP)
activate cGMP-dependent protein kinase I (cGKI), which
reportedly exhibited either anti-fibrotic and/or anti-
hypertrophic effects or did not change the cardiac remo-
deling responses [1-5]. Based on these findings, we and
others suggested that the ability of natriuretic peptides
(NP) to oppose detrimental changes via cGMP/cGKI
might strongly depend on the growth-promoting neuro-
hormonal signals and stresses. Aiming to dissect the
molecular details underlying cardiac cGMP signaling, we
investigated the cysteine-rich LIM-only protein 4 (CRP4)
as a novel target of cardio-vascular cGMP in vivo. CRP4
is phosphorylated at Ser-104 by cGMP/cGKI [6-8] and a
highly related homologue of the muscle LIM protein
CRP3/MLP, which has been linked to dilated and hyper-
trophic cardiomyopathies in mice and humans [9,10].
Materials and methods
A patho-/physiological growth adaption of the heart mus-
cle was induced either by an increase in afterload upon
chronic angiotensin II (AngII) infusions (2 mg/kg/d) or
healthy exercise training using a duration-controlled
swimming protocol in CRP4 knockout (KO), wild type
(WT) and heterozygous (HET) littermates. The extent of
the cardiac growth response was defined by referring
changes in heart weight (HW) to body weight (HW/BW)
and tibia length (HW/TL). Hypertrophic marker genes,
putative effects of AngII on components of the NP/
cGMP/cGKI pathway and the expression pattern of other
members of the CRP protein family were analyzed in total
mRNA and protein preparations isolated from healthy and
hypertrophic ventricles. These experiments were corrobo-
rated by the localization of CRP4 in the myocardium and
Sirius Red staining as a quantitative measure of fibrosis.
Results
CRP4 mRNA and protein levels were significantly
reduced in HET hearts and absent from KO muscles.
HW/BW and HW/TL ratios of all three genotypes did
not differ at baseline, however, cardiomyocyte size and
heart ratios were elevated in CRP4 HET and KO ani-
mals in response to the AngII infusions. Interstitial
fibrosis was significantly stimulated by AngII in CRP4-
deficient and HET hearts, whereas the production of
anti-fibrotic factors such as BNP was diminished.
Importantly, no differences between the genotypes in
cardiac mass or the amount of fibrosis were detected
upon swimming exercises.
Conclusion
The increased susceptibility of CRP4-deficient hearts to
chronic AngII exposure indicates that beneficial effects
of cGMP/cGKI to oppose Gaq-mediated signaling
require cardiac CRP4.
Published: 29 August 2013
* Correspondence: julia.straubinger@uni-tuebingen.de
Pharmakologie, Toxikologie und Klinische Pharmazie, Institut für Pharmazie,
Universität Tübingen, Tübingen, Germany
Straubinger et al. BMC Pharmacology and Toxicology 2013, 14(Suppl 1):P68
http://www.biomedcentral.com/2050-6511/14/S1/P68
© 2013 Straubinger et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
References
1. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D,
Gabrielson KL, Wang Y, Kass DA: Chronic inhibition of cyclic GMP
phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Nature Med 2005, 1:214-222.
2. Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F: Cardiac
hypertrophy is not amplified by deletion of cGMP-dependent protein
kinase I in cardiomyocytes. Proc Natl Acad Sci USA 2010, 107:5646-565.
3. Frantz S, Klaiber M, Baba HA, Oberwinkler H, Volker K, Gabetaner B, Bayer B,
Abebetaer M, Schuh K, Feil R, Hofmann F, Kuhn M: Stress-dependent
dilated cardiomyopathy in mice with cardiomyocyte-restricted
inactivation of cyclic GMP- dependent protein kinase I. Eur Heart J 2013,
34:1233-1244.
4. Klaiber M, Dankworth B, Kruse M, Hartmann M, Nikolaev VO, Yang RB,
Volker K, Gassner B, Oberwinkler H, Feil R, Freichel M, Groschner K,
Skryabin BV, Frantz S, Birnbaumer L, Pongs O, Kuhn M: A cardiac pathway
of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor
for atrial natriuretic peptide. Proc Natl Acad Sci USA 2011,
108:18500-18505.
5. Blanton RM, Takimoto E, Lane AM, Aronovitz M, Piotrowski R, Karas RH,
Kass DA, Mendelsohn ME: Protein kinase g ialpha inhibits pressure
overload-induced cardiac remodeling and is required for the
cardioprotective effect of sildenafil in vivo. J Amer Heart Assoc 2012, 1:
e003731.
6. Huber A, Neuhuber WL, Klugbauer N, Ruth P, Allescher HD: Cysteine-rich
protein 2, a novel substrate for cGMP kinase I in enteric neurons and
intestinal smooth muscle. J Biol Chem 2000, 275:5504-5511.
7. Schmidtko A, Gao W, Sausbier M, Rauhmeier I, Sausbier U, Niederberger E,
Scholich K, Huber A, Neuhuber W, Allescher HD, Hofmann F, Tegeder I,
Ruth P, Geisslinger G: Cysteine-rich protein 2, a novel downstream
effector of cGMP/cGMP-dependent protein kinase I-mediated persistent
inflammatory pain. J Neurosci 2008, 28:1320-1330.
8. Zhang T, Zhuang S, Casteel DE, Looney DJ, Boss GR, Pilz RB: A cysteine-rich
LIM- only protein mediates regulation of smooth muscle-specific gene
expression by cGMP-dependent protein kinase. J Biol Chem 2007,
282:33367-33380.
9. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC,
Chien KR, Caroni P: MLP-deficient mice exhibit a disruption of cardiac
cytoarchitectural organization, dilated cardiomyopathy, and heart failure.
Cell 1997, 88:393-403.
10. Geier C, Perrot A, Ozcelik C, Binner P, Counsell D, Hoffmann K, Pilz B,
Martiniak Y, Gehmlich K, van der Ven PF, Furst DO, Vornwald A, von
Hodenberg E, Nurnberg P, Scheffold T, Dietz R, Osterziel KJ: Mutations in
the human muscle LIM protein gene in families with hypertrophic
cardiomyopathy. Circulation 2003, 107:1390-1395.
doi:10.1186/2050-6511-14-S1-P68
Cite this article as: Straubinger et al.: Cardiac cGMP/cGMP-dependent
protein kinase I signalling requires cysteine-rich LIM-only protein 4
(CRP4) to oppose angiotensin II induced hypertrophy and fibrosis. BMC
Pharmacology and Toxicology 2013 14(Suppl 1):P68.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Straubinger et al. BMC Pharmacology and Toxicology 2013, 14(Suppl 1):P68
http://www.biomedcentral.com/2050-6511/14/S1/P68
Page 2 of 2
